# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Ironwood Pharmaceuticals (NASDAQ:IRWD) sees FY2025 sales of $260.000 million-$290.000 million vs $270.600 million analyst estim...
Ironwood Pharmaceuticals (NASDAQ:IRWD) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate...